NICE asks for more info on Gilead's Zydelig; Dr. Reddy's closes UCB buy;

@FiercePharma: UPDATED: U.S. court nixes Teva's Copaxone patent--again. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck inks $5.9M settlement to wrap up AzaSite off-label investigation. Article | Follow @CarlyHFierce

> U.K. cost watchdogs have asked for more information on Gilead's ($GILD) Zydelig before they decide if the drug can be a cost-effective option in patients with chronic lymphocytic leukemia. More

> Dr. Reddy's Laboratories ($RDY) has closed its acquisition of some of UCB's South Asian branded products. More

> The FDA and international partners have moved against more than 1,050 websites that sell counterfeit meds and medical devices. Report

Medical Device News

@FierceMedDev: UPDATED with comments from Cynvenio CEO: Cynvenio Biosystems ropes in $25M for liquid biopsy technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Chinese med tech gets the WHO's OK for circumcision device. Article | Follow @EmilyWFierce

> FDA hints it will show 'additional flexibility' when it comes to approving device clinical trials. Report

> House repeals medical device tax by veto-proof margin. More

Biotech News

@FierceBiotech: ICYMI yesterday: Merck KGaA hustling a promising anti-malaria drug into human studies. Report | Follow @FierceBiotech

@JohnCFierce: $TKMR down 15% on the ebola miss. | Follow @JohnCFierce

@DamianFierce: FierceBiotech Radio releases its first double album. This is our All Eyez on Me. More | Follow @DamianFierce

> Lilly and Teva tout new migraine data amid a crowded race. Story

> Antibiotics biotech Nabriva shoots for a $92M IPO. News

> Tekmira's Ebola drug comes up short in Phase II. Article

And Finally... Sanofi ($SNY) has launched an awareness campaign in Lebanon on how to manage diabetes while observing Ramadan. More

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.